InflaRx Shares Soar 40% on FDA Emergency Use Authorization of Gohibic for Covid-19
05 Abril 2023 - 12:30PM
Dow Jones News
By Denny Jacob
InflaRx NV shares were on pace Wednesday for its best three-day
stretch on record, a day after Gohibic, a monoclonal anti-human
complement factor C5a antibody it is developing, was granted
emergency use authorization by the U.S. Food and Drug
Administration.
The German clinical-stage biopharmaceutical company said
emergency use authorization was indicated for the treatment of
Covid-19 in hospitalized patients when initiated within 48 hours of
administering invasive mechanical ventilation.
InflaRx said it also completed meetings with the European
Committee for Medicinal Products for Human Use regarding a planned
marketing authorization application with the European Medicines
Agency.
Chief Executive Niels Riedemann said that despite the
availability of vaccines and other Covid-19 treatments, many
patients still develop viral sepsis and progress to a critical
status, often requiring invasive mechanical ventilation.
Shares were recently up 92% at Wednesday's intraday high, its
largest intraday percentage increase on record. The stock is also
on pace for its highest close since Feb. 17, 2021, when it closed
at $6.34.
Trading was paused for volatility three times Wednesday and most
recently resumed at 10:20 a.m. ET. Roughly 40.8 million shares had
traded as of 10:33 a.m. ET, compared with its 65-day average volume
of roughly 338,698 shares.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
April 05, 2023 11:15 ET (15:15 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
InflaRx NV (NASDAQ:IFRX)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
InflaRx NV (NASDAQ:IFRX)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024
